Background/Aims/Methods: To determine the frequency of Helicobacter pylori infection (Hp-I) in 73 patients with myelodysplastic syndromes (MDS) and 40 controls, serologic analyses of Hp and 13C-urease breath tests (INFAI) were performed. Gastric mucosal biopsy specimens were obtained to determine the presence of Hp-I using a rapid urease test, i.e. the Campylobacter-like organism (CLO) test, and cresyl violet staining. Peripheral blood (PB) flow cytometry for CD3, CD4, CD8, CD14, CD19 and CD34 was conducted in 35 patients and in controls. Results:Hp-I was detected by: (a) serology in 75.34% of patients (p = 0.000), (b) INFAI in 57.69% of patients, (c) CLO in 60.71% of patients and (d) histological confirmation in 80.36% of patients (p = 0.001). No correlation between Hp-I and CD3, CD4, CD8, CD14, CD19 expression, leukemic transformation or death was observed. However, in 20 cases, significant variation in the PB lymphocytic proportion possibly attributable to Hp-I was ascertained, in contrast to the expected MDS ratio. Conclusion: Although there is no evidence for a causal relationship between Hp-I and MDS, the increased prevalence of Hp-I among the MDS patients is an interesting finding that deserves further investigation as it may indicate a common factor causing susceptibilities to both MDS and Hp-I or that Hp might influence the pathophysiology of MDS.

1.
Nguyen PL: The myelodysplastic syndromes. Hematol Oncol Clin North Am 2009;23:675–691.
2.
Kountouras J, Mylopoulos N, Boura P, Bessas C, Chatzopoulos D, Venizelos J, Zavos C: Relationship between Helicobacter pylori infection and glaucoma. Ophthalmology 2001;108:599–604.
3.
Kountouras J, Mylopoulos N, Chatzopoulos D, Zavos C, Boura P, Konstas AG, Venizelos J: Eradication of Helicobacter pylori may be beneficial in the management of chronic open-angle glaucoma. Arch Intern Med 2002;162:1237–1244.
4.
Kountouras J, Zavos C, Chatzopoulos D, Katsinelos P: New aspects of Helicobacter pylori infection involvement in gastric oncogenesis. J Surg Res 2008;146:149–158.
5.
Kountouras J, Zavos C, Chatzopoulos D: New concepts of molecular biology on gastric carcinogenesis. Hepatogastroenterology 2005;52:1305–1312.
6.
Kountouras J, Zavos C, Diamantidis MD, Deretzi G, Grigoriadis N, Tsapournas G, Katsinelos P, Molyvas E: A concept of Helicobacter pylori and stress-secreted mast cells’ potential involvement in brain metastases. J Neuroimmunol 2009;209:121–122.
7.
Cines DB, Liebman H, Stasi R: Pathobiology of secondary immune thrombocytopenia. Semin Hematol 2009;46(1 suppl 2):S2–S14.
8.
Kountouras J, Deretzi G, Zavos C, Karatzoglou P, Touloumis L, Nicolaides T, Chatzopoulos D, Venizelos I: Association between Helicobacter pylori infection and acute inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol 2005;12:139–143.
9.
Neuwirtova R, Karban J: The decrease of B lymphocytes in MDS – what is the significance of it? Abstr 9th Int Symp Myelodysplastic Syndromes. Leuk Res 2007;31(suppl 1):S70.
10.
Marisavljevic D, Kraguljac N, Rolovic Z: Immunologic abnormalities in myelodysplastic syndromes: clinical features and characteristics of the lymphoid population. Med Oncol 2006;23:385–392.
11.
Shioi Y, Tamura H, Yokose N, Satoh C, Dan K, Ogata K: Increased apoptosis of circulating T cells in myelodysplastic syndromes. Leuk Res 2007;31:1641–1648.
12.
Anonymous: Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983;i:1273–1275.
13.
Anonymous: Epidemiology of, and risk factors for, Helicobacter pylori infection among 3,194 asymptomatic subjects in 17 populations. The EUROGAST Study Group. Gut 1993;34:1672–1676.
14.
Apostolopoulos P, Vafiadis-Zouboulis I, Tzivras M, Kourtessas D, Katsilambros N, Archimandritis A: Helicobacter pylori(H. pylori) infection in Greece: the changing prevalence during a ten-year period and its antigenic profile. BMC Gastroenterol 2002;2:11.
15.
Weinstein WM: Gastritis and gastropathies; in Sleisenger MH, Fordtran JS (eds): Gastrointestinal Disease: Pathology, Diagnosis, Management, ed 5. Philadelphia, Saunders, 1993, pp 545–571.
16.
Peterson WL, Graham DY: Helicobacter pylori; in Feldman M, Scharschmidt B, Sleisenger MH (eds): Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management, ed 6. Philadelphia, Saunders, 1997, pp 604–619.
17.
Kountouras J, Zavos C, Chatzopoulos D: Primary open-angle glaucoma: pathophysiology and treatment. Lancet 2004;364:1311–1312.
18.
Kountouras J, Gavalas E, Zavos C, Stergiopoulos C, Chatzopoulos D, Kapetanakis N, Gisakis D: Alzheimer’s disease and Helicobacter pylori infection: defective immune regulation and apoptosis as proposed common links. Med Hypotheses 2007;68:378–388.
19.
Abdalla AM, Sordillo EM, Hanzely Z, Perez-Perez GI, Blaser MJ, Holt PR, Moss SF: Insensitivity of the CLOtest for H. pylori, especially in the elderly. Gastroenterology 1998;115:243–244.
20.
Young HS, Keeffe EB: Complications of gastrointestinal endoscopy; in Sleisenger MH, Fordtran JS (eds): Gastrointestinal Disease: Pathology, Diagnosis, Management, ed 5. Philadelphia, Saunders, 1993, pp 301–316.
21.
Mönkemüller K, Fry LC, Malfertheiner P, Schuckardt W: Gastrointestinal endoscopy in the elderly: current issues. Best Pract Res Clin Gastroenterol 2009;23:821–827.
22.
Ria R, Moschetta M, Reale A, Mangialardi G, Castrovilli A, Vacca A, Dammacco F: Managing myelodysplastic symptoms in elderly patients. Clin Interv Aging 2009;4:413–423.
23.
Fennerty MB: Helicobacter pylori. Arch Intern Med 1994;154:721–727.
24.
Pathak CM, Bhasin DK, Khanduja KL: Urea breath test for Helicobacter pylori detection: present status. Trop Gastroenterol 2004;25:156–161.
25.
Kountouras J: Helicobacter pylori: an intruder involved in conspiring glaucomatous neuropathy. Br J Ophthalmol 2009;93:1413–1415.
26.
Kordasti SY, Afzali B, Lim Z, Ingram W, Hayden J, Barber L, Matthews K, Chelliah R, Guinn B, Lombardi G, Farzaneh F, Mufti GJ: IL-17-producing CD4+ T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome. Br J Haematol 2009;145:64–72.
27.
Diamantidis M, Dimoudis S, Klonizakis P, Badekas K, Koutourli K, Haralambidou-Vranitsa S, Ioannidou-Papagiannaki E: The role of apoptosis and current therapeutic challenges in myelodysplastic syndromes. Hippokratia 2007;11:178–182.
28.
Elisseeva OA, Oka Y, Tsuboi A, Ogata K, Wu F, Kim EH, Soma T, Tamaki H, Kawakami M, Oji Y, Hosen N, Kubota T, Nakagawa M, Yamagami T, Hiraoka A, Tsukaguchi M, Udaka K, Ogawa H, Kishimoto T, Nomura T, Sugiyama H: Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies. Blood 2002;99:3272–3279.
29.
Solnick JV, Franceschi F, Roccarina D, Gasbarrini A: Extragastric manifestations of Helicobacter pylori infection-other Helicobacter species. Helicobacter 2006;11(suppl 1):46–51.
30.
Jackson SC, Beck P, Buret AG, O’Connor PM, Meddings J, Pineo G, Poon MC: Long-term platelet responses to Helicobacter pylori eradication in Canadian patients with immune thrombocytopenic purpura. Int J Hematol 2008;88:212–218.
31.
Bai Y, Wang Z, Bai X, Yu Z, Cao L, Zhang W, Ruan C: Cross-reaction of antibody against Helicobacter pylori urease B with platelet glycoprotein IIIa and its significance in the pathogenesis of immune thrombocytopenic purpura. Int J Hematol 2009;89:142–149.
32.
Ferrucci PF, Zucca E: Primary gastric lymphoma pathogenesis and treatment: what has changed over the past 10 years? Br J Haematol 2007;136:521–538.
33.
Bussiere FI, Chaturvedi R, Asim M, Hoek KL, Cheng Y, Gainor J, Scholz A, Khan WN, Wilson KT: Low multiplicity of infection of Helicobacter pylori suppresses apoptosis of B lymphocytes. Cancer Res 2006;66:6834–6842.
34.
Malik AA, Ganti AK, Potti A, Levitt R, Hanley JF: Role of Helicobacter pylori infection in the incidence and clinical course of monoclonal gammopathy of undetermined significance. Am J Gastroenterol 2002;97:1371–1374.
35.
Rajkumar SV, Kyle RA, Plevak MF, Murray JA, Therneau TM: Helicobacter pylori infection and monoclonal gammopathy of undetermined significance. Br J Haematol 2002;119:706–708.
36.
Papadaki HA, Pontikoglou C, Stavroulaki E, Minadakis G, Eliopoulos DA, Pyrovolaki K, Skordilis P, Eliopoulos GD: High prevalence of Helicobacter pylori infection and monoclonal gammopathy of undetermined significance in patients with chronic idiopathic neutropenia. Ann Hematol 2005;84:317–320.
37.
Papadaki HA, Pontikoglou C, Eliopoulos DG, Pyrovolaki K, Spyridaki R, Eliopoulos GD: Helicobacter pylori infection is probably the cause of chronic idiopathic neutropenia (CIN)-associated splenomegaly. Am J Hematol 2006;81:142–144.
38.
Papadaki HA, Skordilis P, Minadakis G, Roussomoustakaki M, Katrinakis G, Psyllaki M, Tzardi M, Kouroumalis E, Eliopoulos GD: Complete regression of primary gastric plasmacytoma following Helicobacter pylori eradication. Ann Hematol 2003;82:589–592.
39.
Arima N, Tsudo M: Extragastric mucosa-associated lymphoid tissue lymphoma showing the regression by Helicobacter pylori eradication therapy. Br J Haematol 2003;120:790–792.
40.
Diamantidis MD, Ioannidou – Papagiannaki E, Tsapournas G, Haralambidou–Vranitsa S, Klonizakis P, Klonizakis I: Myelodysplastic syndromes (MDS): factors increasing probability for leukaemic transformation in a Greek series of patients from a single institution. Abstr 10th Int Symp Myelodysplastic Syndromes. Leuk Res 2009;33(suppl 1):S104.
41.
Diamantidis MD, Ioannidou-Papagiannaki E, Kountouras J, Mandala E, Tsapournas G, Frida-Michailidou I, Klonizakis P, Haralambidou-Vranitsa S, Makrovasilie F, Samara M, Parapanisiou E, Klonizakis I: Does Helicobacter pylori infection participate in the pathogenesis of myelodysplastic syndromes (MDS)? Abstr 10th Int Symp on Myelodysplastic Syndromes. Leuk Res 2009;33(suppl 1):S103–S104.
42.
Cukrová V, Neuwirtová R, Dolezalová L, Belicková M, Bartůnková J, Jonásová A, Cermák J, Homolková H, Maliková I: Defective cytotoxicity of T lymphocytes in myelodysplastic syndrome. Exp Hematol 2009;37:386–394.
43.
Amin HM, Jilani I, Estey EH, Keating MJ, Dey AL, Manshouri T, Kantarjian HM, Estrov Z, Cortes JE, Thomas DA, Giles FJ, Albitar M: Increased apoptosis in bone marrow B lymphocytes but not T lymphocytes in myelodysplastic syndrome. Blood 2003;102:1866–1868.
44.
Fozza C, Contini S, Galleu A, Simula MP, Virdis P, Bonfigli S, Longinotti M: Patients with myelodysplastic syndromes display several T-cell expansions, which are mostly polyclonal in the CD4+ subset and oligoclonal in the CD8+ subset. Exp Hematol 2009;37:947–955.
45.
Diamantidis MD, Ioannidou-Papagiannaki E, Kountouras J, Mandala E, Klonizakis P, Frida-Michailidou I, Tsapournas G, Haralambidou-Vranitsa S, Klonizakis I: Helicobacter pylori infection might protect from the leukaemic transformation of myelodysplastic syndromes. Med Hypotheses 2008;71:159–160.
46.
Zavos C: A revision of the possible dual role of Helicobacter pylori in myelodysplastic syndrome. Med Hypotheses 2008;71:161.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.